Interchange Capital Partners’s AstraZeneca AZN Stock Holding History

Interchange Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$263K	Sell	1,615 -2	-0.1%	-$333	0.04%	358
2026 Q2	$304K	Buy	+1,617	New	+$304K	0.06%	293
2026 Q1	–	Sell	-1,947	Closed	-$358K	–	320
2025 Q4	$358K	Buy	1,947 +339	+21%	+$59.5K	0.07%	260
2025 Q3	$247K	Buy	+1,608	New	+$243K	0.05%	308
2024 Q4	–	Sell	-1,504	Closed	-$235K	–	269
2024 Q3	$235K	Sell	1,504 -36	-2%	-$5.81K	0.08%	234
2024 Q2	$240K	Buy	+1,540	New	+$232K	0.09%	229
2021 Q1	–	Sell	-954	Closed	-$95K	–	304
2020 Q4	$95K	Buy	+954	New	+$101K	0.05%	312

Other funds holding AZN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Interchange Capital Partners's AZN Position: Q3 2026 in Review

Interchange Capital Partners reduced its AstraZeneca (AZN) stake by 0.12% in Q3 2026, selling an estimated $333 and leaving 1,615 shares worth $263K. The position accounts for 0.04% of the portfolio, ranked #358.

Interchange Capital Partners first reported a position in AZN in Q4 2020 and has held it in 7 quarters since. The position peaked at $358K in Q4 2025. 918 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Interchange Capital Partners held 1,615 shares of AstraZeneca worth $263K as of Q3 2026.
Interchange Capital Partners sold 2 AstraZeneca shares in Q3 2026, an estimated $333.
AstraZeneca made up 0.04% of Interchange Capital Partners's portfolio in Q3 2026, its #358 holding.
Interchange Capital Partners first reported a position in AstraZeneca in Q4 2020 and has held it in 7 quarters since.
Interchange Capital Partners's AstraZeneca position peaked at $358K in Q4 2025.
918 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Interchange Capital Partners's 13F filing for Q3 2026, filed 28 Oct 2026.